- Home
- HRMY vs VICR Comparison
HRMY vs VICR Comparison
Compare HRMY & VICR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- VICR
- Stock Information
- Founded
- HRMY 2017
- VICR 1981
- Country
- HRMY United States
- VICR United States
- Employees
- HRMY N/A
- VICR N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- VICR Industrial Machinery/Components
- Sector
- HRMY Health Care
- VICR Technology
- Exchange
- HRMY Nasdaq
- VICR Nasdaq
- Market Cap
- HRMY 1.8B
- VICR 1.9B
- IPO Year
- HRMY 2020
- VICR N/A
- Fundamental
- Price
- HRMY $34.00
- VICR $46.48
- Analyst Decision
- HRMY Strong Buy
- VICR Hold
- Analyst Count
- HRMY 9
- VICR 2
- Target Price
- HRMY $54.44
- VICR $43.00
- AVG Volume (30 Days)
- HRMY 642.5K
- VICR 239.2K
- Earning Date
- HRMY 08-05-2025
- VICR 07-22-2025
- Dividend Yield
- HRMY N/A
- VICR N/A
- EPS Growth
- HRMY 13.13
- VICR N/A
- EPS
- HRMY 2.62
- VICR 0.51
- Revenue
- HRMY $744,852,000.00
- VICR $369,154,000.00
- Revenue This Year
- HRMY $20.10
- VICR $15.61
- Revenue Next Year
- HRMY $18.01
- VICR $14.71
- P/E Ratio
- HRMY $13.10
- VICR $90.23
- Revenue Growth
- HRMY 20.62
- VICR N/A
- 52 Week Low
- HRMY $26.47
- VICR $34.25
- 52 Week High
- HRMY $41.61
- VICR $65.70
- Technical
- Relative Strength Index (RSI)
- HRMY 58.91
- VICR 56.18
- Support Level
- HRMY $31.70
- VICR $44.99
- Resistance Level
- HRMY $35.08
- VICR $47.57
- Average True Range (ATR)
- HRMY 0.95
- VICR 1.71
- MACD
- HRMY 0.27
- VICR 0.09
- Stochastic Oscillator
- HRMY 71.80
- VICR 74.35
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About VICR Vicor Corporation
Vicor Corp manufactures and markets modular power components and complete power systems for converting electrical power. It provides modular power converters and configurable products, power component products and integrated circuits, and related products. Its products include Converters, Power Systems, Filters, Custom Power Systems, Input Modules, and others.